ArticleBone & joint open2022

Cost-effectiveness of adalimumab for early-stage Dupuytren's disease : an economic evaluation based on a randomized controlled trial and individual-patient simulation model.

Helen Dakin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.